2020052-55-3 Usage
Uses
Used in Pharmaceutical Industry:
(S)-N-(3-(3-ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-ylamino)phenyl)acrylamide is used as a potential therapeutic agent for targeting specific biological pathways. Its kinase inhibitory activity makes it a candidate for the development of drugs aimed at treating various diseases, including cancer and other conditions involving abnormal cell signaling.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (S)-N-(3-(3-ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-ylamino)phenyl)acrylamide serves as a valuable compound for studying the structure-activity relationship of kinase inhibitors. Its complex structure allows researchers to explore various modifications and optimizations to enhance its potency, selectivity, and pharmacokinetic properties.
Used in Drug Design and Development:
(S)-N-(3-(3-ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-ylamino)phenyl)acrylamide is utilized in drug design and development processes to create novel inhibitors with improved efficacy and safety profiles. Its unique molecular architecture provides a foundation for the development of targeted therapies that can potentially revolutionize the treatment of various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 2020052-55-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,0,2,0,0,5 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2020052-55:
(9*2)+(8*0)+(7*2)+(6*0)+(5*0)+(4*5)+(3*2)+(2*5)+(1*5)=73
73 % 10 = 3
So 2020052-55-3 is a valid CAS Registry Number.
2020052-55-3Relevant academic research and scientific papers
INHIBITORS OF CYCLIN-DEPENDENT KINASES
-
, (2017/05/28)
The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
